C1QTNF6
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
FITC
Applikationshinweise
ELISA: (direct or indirect: 1:200-1:500). Immunohistochemistry (paraffin sections): 1:200. Western blot: (1:200-1:500 using ECL. Suggested blocking and dilution buffer is PBST with 0.05 % Tween 20 and 5 % skim milk. Suggested incubation time is 1 hour at room temperature). Optimal conditions should be determined individually for each application.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.
Konservierungsmittel
Without preservative
Lagerung
-20 °C
Informationen zur Lagerung
Stable for at least 1 year after receipt when stored at -20°C.
Target
CTRP6 (C1QTNF6)
(Complement C1q Tumor Necrosis Factor-Related Protein 6 (C1QTNF6))
MGC148634 antikoerper, CTFP6 antikoerper, CTRP6 antikoerper, ZACRP6 antikoerper, 2810036M19Rik antikoerper, Ctrp6 antikoerper, C1q and TNF related 6 antikoerper, C1q and tumor necrosis factor related protein 6 antikoerper, C1QTNF6 antikoerper, C1qtnf6 antikoerper
Hintergrund
CTRP6 mediates the phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) in skeletal muscle cells, subsequently mediating glycogen accumulation and fatty acid oxidation. It induces the expression of the potent anti-inflammatory cytokine IL-10 in macrophages. CTRP6 may be a potential serum marker for hepatocellular carcinoma, contributing to tumor angiogenesis by activating the Akt pathway. CTRP6 was also shown to be associated with obesity, type 1 diabetes mellitus (T1D), vitiligo (depigmentation of the skin) and ASFV (African Swine Fever Virus). CTRP6 forms homotrimers and higher-order oligomers and it may also form heteromeric complexes with CTRP1. May be involved in kidney inflammation.